GGT Assay Kits

Assay Principle

Gamma-glutamyl transferase (GGT) catalyzes the transfer of gamma-glutamyl groups between peptides and amino acids, playing a central role in glutathione metabolism and amino acid transport across cell membranes. A GGT assay typically uses a synthetic gamma-glutamyl donor substrate (glutamyl p-nitroaniline) together with an acceptor (typically glycylglycine); GGT catalyzes transfer of the gamma-glutamyl group to the acceptor, releasing free p-nitroaniline, a chromogenic product with a characteristic absorption peak at approximately 405 nm. Activity is calculated from the rate of absorbance change over time, providing a direct kinetic readout of enzymatic turnover without requiring a secondary coupling reaction.

Protocol highlights and purchasing considerations

Protocol Highlights

GGT is widely used clinically and preclinically as a marker of hepatobiliary function, since serum GGT rises with cholestasis, alcohol-induced liver injury, and various forms of hepatotoxicity, making this assay a standard component of liver and drug toxicity panels in pharmaceutical research. Kits are validated for serum, plasma, and animal tissue homogenates, with reported sensitivity around 0.9 U/L and detection ranges extending close to 400 U/L, comfortably spanning both normal and markedly elevated GGT levels seen in hepatobiliary disease models. Assay times are brief, typically around 20 minutes, and most validated sample types require no dilution, which simplifies workflow relative to some of the more concentration-sensitive enzyme assays in this series. Because GGT is a component of essentially every standard liver function panel, researchers often run it alongside ALT, AST, and ALP measurements from the same sample set, so confirming sample volume requirements across the full panel is a practical planning step.

Assay Kit Purchasing Considerations

Since the p-nitroaniline release chemistry used to measure GGT activity is standard across suppliers, validated sample compatibility and detection range relative to expected disease-model elevation are the primary differentiators. Because GGT is such a well-established hepatotoxicity biomarker, confirming that a kit's detection range comfortably captures the fold-elevations typical of the specific toxicant or disease model under study (which can range from modest for mild cholestasis to substantial for severe hepatocellular injury) is a useful step in assay selection. For studies incorporating GGT into a broader liver panel, choosing a supplier that offers compatible ALT, AST, and ALP kits validated on the same sample types can streamline both protocol design and cross-assay data interpretation. As with any activity assay, it's good practice to review the full protocol before deciding on a kit, since the manual often reveals practical details, such as incubation times, control requirements, and data analysis steps, that aren't captured in the product summary alone.